Amusedobserver, as always, u make alot of sense. Scientists as diggers? I don't think too many scientists could survive Kalgoorlie in "Diggers & Dealers" but that's where they should go.
Biopharma in Australia has become a bit like mining, misrepresentations about tenements, pumping and dumping, downramping, brokers, UK based fundies providing odd disclosure notices either side of the new year, it all seems a little like a case study of the Bendigo share market circa 1870.
I think below sub$20 is an overreaction if the company's dose sales r believable and the secondary treatment retains its credibility from b4 2day.
Quarterly sales doses, which management mysteriously suspended (can the governance get any worse?), were QoQ tracking up by 10% a quarter, b4 the AUD started tanking against the USD and the € started holding its own against the AUD post Draghi's quantitative easing the Southern Europeans out of their no tax no revenue mess.
SRX should be worth at least $25 based on their last published quarterly dose figures. Again, can you believe, anymore?
(20min delay)